Compare Novartis AG (NVS) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vanguard Total International Stock Index Fund ETF — how do they compare? Novartis AG trades at $143.32 (market cap $268.57B), while Vanguard Total International Stock Index Fund ETF trades at $84.62 (market cap $665.70B). The key difference: Vanguard Total International Stock Index Fund ETF is far larger — about 2.5× Novartis AG's market cap, and Novartis AG pays a 3.31% dividend while Vanguard Total International Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Vanguard Total International Stock Index Fund ETF for 55 Days on average.
| NVS | VXUS | |
|---|---|---|
Market Cap | $268.57B | $665.70B |
Volume | 1,532,573 | 4,864,744 |
Sector | Health | Sector/Thematic |
52-Week High | $168.62 | $88.41 |
52-Week Low | $121.80 | $72.17 |
Typical Hold Time | 82 Days | 55 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
VXUS, the Vanguard Total International Stock ETF, trades at $84.56, down 0.26% with a bearish technical signal. The ETF provides diversified exposure to international developed and emerging markets outside the US. Recent news highlights its role in portfolio diversification and institutional buying interest, though technical indicators show selling pressure across moving averages and oscillators.
The outlook for VXUS hinges on international market performance relative to US equities, with potential for long-term growth diversification. Risks include currency fluctuations and regional economic volatility. Institutional accumulation suggests confidence in international equity exposure as a strategic portfolio component.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
